Opthea forms Medical Advisory Board with retinal disease experts

Opthea announces the formation of its Medical Advisory Board composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB’s role is to advise the Company on opportunities to address the unmet medical needs of patients with retinal diseases and to inform the Company’s development efforts, such as the sozinibercept clinical program in wet AMD. The formation of the MAB comes at a crucial stage for the Company as it prepares for Phase 3 topline data read-out of its two pivotal trials of sozinibercept in wet AMD and continues to advance BLA and go-to-market preparations. Opthea’s newly formed MAB consists of the following members: David S. Boyer, MD, is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous, and a leading clinical researcher for new treatments in macular degeneration and diabetic macular edema. He is Senior Partner at the Retina-Vitreous Associates Medical Group, and an Adjunct Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, California. Andrew Chang, AM, MBBS, PhD FRANZCO, FRACS, is a vitreoretinal surgeon and ophthalmologist. He holds academic appointments of Conjoint Professor of the Department of Surgery UNSW and Clinical Associate Professor at the University of Sydney. He is a consultant ophthalmologist and the Head of Ophthalmology at the Sydney Eye Hospital, and the Medical Director of Sydney Retina Clinic, Australia. Frank G. Holz, MD, FEBO, FARVO, is Professor and Chairman of the Department of Ophthalmology at the University of Bonn, Germany. Anat Loewenstein, MD, MHA, is Professor and Director of the Division of Ophthalmology at the Tel Aviv Medical Center, VP Ambulatory Services at the Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, Israel, and President of EURETINA. Dante Pieramici, MD, is a Managing Partner at California Retina Consultants and a member of the Medical Leadership Board of the Retina Consultants of America. Carl Regillo, MD, is the Director of the Retina Service Unit of Wills Eye Hospital in Philadelphia, Professor of Ophthalmology at Thomas Jefferson University School of Medicine, as well as founder and former Director of the Wills Eye Clinical Retina Research Unit. Patricio G. Schlottmann, MD, is Ophthalmology Director and Retina Specialist at the Medical University, as well as Head of Clinical Research at the Charles Research Center of Ophthalmology, Buenos Aires, Argentina. Tien Y Wong, MD, PhD, is a practicing retinal specialist with a research portfolio on retinal diseases, ocular imaging, artificial intelligence and digital technology. He serves as Chair Professor and the Founding Head of Tsinghua Medicine at Tsinghua University, Beijing, China. Eric Souied MD, PhD, is the Head of the Ophthalmology Department at the Intercommunal Hospital of Creteil and Henri Mondor Hospital. He is also Professor of Ophthalmology at the University of Paris-Est Creteil.